Nkarta, Inc. (NKTX)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
1.93 USD
-0.10
(-4.926%) ⇩
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:06 a.m. EDT
The investment case here is fundamentally broken despite the optimistic analyst consensus. The company is burning cash aggressively with negative free cash flow and operating cash flow, while returning negative equity to shareholders. The balance sheet shows significant leverage relative to equity, and the return on assets and equity are deeply negative. While the stock price has recovered somewhat recently, the five-year trajectory remains catastrophic, having lost over 92% of its value. The market has correctly priced this as a distressed biotech play rather than a growth story. With no dividend to provide income and a high risk of capital erosion due to continued burn, the only logical move is to stay away until the company demonstrates a clear path to profitability or a successful major milestone that justifies the current valuation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.123030 |
| AutoARIMA | 0.123469 |
| AutoETS | 0.123470 |
| MSTL | 0.125500 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 1.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.101 |
| Excess Kurtosis | 0.07 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29.684 |
| Market Cap | 138,235,840 |
| Forward P/E | -1.10 |
| Beta | 0.94 |
| Website | https://www.nkartatx.com |
As of Oct. 10, 2026, 2:06 a.m. EDT: Options activity is extremely thin with negligible open interest across all expirations. There is no meaningful positioning in either calls or puts to indicate a specific speculative bias. Implied volatility is low and flat, suggesting a lack of active hedging or directional bets by the broader options community.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.11739129 |
| Address1 | 1,150 Veterans Boulevard |
| All Time High | 79.16 |
| All Time Low | 1.28 |
| Ask | 2.47 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 632,870 |
| Average Daily Volume3 Month | 605,347 |
| Average Volume | 605,347 |
| Average Volume10Days | 632,870 |
| Beta | 0.938 |
| Bid | 1.47 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 3.459 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.93 |
| Current Ratio | 7.981 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.07 |
| Day Low | 1.91 |
| Debt To Equity | 29.684 |
| Display Name | Nkarta |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,340,800 |
| Earnings Timestamp Start | 1,794,340,800 |
| Ebitda | -113,441,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.256 |
| Enterprise Value | 29,010,846 |
| Eps Current Year | -1.70667 |
| Eps Forward | -1.75333 |
| Eps Trailing Twelve Months | -1.58 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.5966 |
| Fifty Day Average Change | -0.6666001 |
| Fifty Day Average Change Percent | -0.25672036 |
| Fifty Two Week Change Percent | -11.739129 |
| Fifty Two Week High | 3.72 |
| Fifty Two Week High Change | -1.7900001 |
| Fifty Two Week High Change Percent | -0.4811828 |
| Fifty Two Week Low | 1.7 |
| Fifty Two Week Low Change | 0.2299999 |
| Fifty Two Week Low Change Percent | 0.13529405 |
| Fifty Two Week Range | 1.7 - 3.72 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,594,387,800,000 |
| Float Shares | 60,522,948 |
| Forward Eps | -1.75333 |
| Forward P E | -1.1007625 |
| Free Cashflow | -55,131,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 106 |
| Fullday Change | -0.13 |
| Fullday Change Percent | -6.403941 |
| Fullday Price | 1.93 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04875 |
| Held Percent Institutions | 0.82897 |
| Implied Shares Outstanding | 71,624,791 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-07-10 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. |
| Long Name | Nkarta, Inc. |
| Market | us_market |
| Market Cap | 138,235,840 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_544531597 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -117,324,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 196,968,175 |
| Number Of Analyst Opinions | 6 |
| Open | 2.05 |
| Operating Cashflow | -92,756,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Phone | 925 407 1049 |
| Previous Close | 2.03 |
| Price Eps Current Year | -1.1308571 |
| Price Hint | 4 |
| Price To Book | 0.5579647 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.846 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.1 |
| Regular Market Change Percent | -4.92611 |
| Regular Market Day High | 2.07 |
| Regular Market Day Low | 1.91 |
| Regular Market Day Range | 1.91 - 2.07 |
| Regular Market Open | 2.05 |
| Regular Market Previous Close | 2.03 |
| Regular Market Price | 1.93 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 1,476,705 |
| Return On Assets | -0.19574 |
| Return On Equity | -0.38759 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 71,624,791 |
| Shares Percent Shares Out | 0.0511 |
| Shares Short | 3,661,385 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,438,080 |
| Short Name | Nkarta, Inc. |
| Short Percent Of Float | 0.0639 |
| Short Ratio | 5.8 |
| Source Interval | 15 |
| State | CA |
| Symbol | NKTX |
| Target High Price | 14.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 10.83333 |
| Target Median Price | 10.5 |
| Total Cash | 182,764,000 |
| Total Cash Per Share | 2.552 |
| Total Debt | 73,539,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.58 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.54845 |
| Two Hundred Day Average Change | -0.61845005 |
| Two Hundred Day Average Change Percent | -0.24267694 |
| Type Disp | Equity |
| Volume | 1,476,705 |
| Website | https://www.nkartatx.com |
| Zip | 94,080 |